第十届全国生物物理学术大会摘要格式

中国生物物理学会将于2006年5月23~28日在山东青岛市府新大厦举行“第十次中国生物物理学术大会暨第八届全国会员代表大会”。会议相关信息请登陆中国生物物理学会主页（www.bsc.org.cn）“第十次中国生物物理学术大会”栏目查询。     

肿瘤血管靶向药物的研究进展

肿瘤血管在实体瘤的发生发展中具有重要的作用,靶向肿瘤血管的新药研发已成为一个热点领域.抗肿瘤血管的治疗策略分为肿瘤新生血管生成抑制剂（tumor angiogenesis inhibitor,TAI）和肿瘤血管靶向药物（vascular targeting agents,VTAs）两方面的研究.肿瘤新生血管生成抑制剂旨在抑制肿瘤新生血管生成的过程,而肿瘤血管靶向药物则是通过快速而有选择性地破坏肿瘤血管功能,使肿瘤血供受阻,导致肿瘤坏死.VTA类药物分为两类：一是小分子抑制剂（small molecule agents）,利用肿瘤血管和正常组织血管存在的差别选择性地破坏肿瘤血管;另一种是生物制剂（biological agents）,借助能够特异结合肿瘤血管的配体将毒素、凝血诱导剂、凋亡诱导分子等运送到肿瘤血管,引起血管阻塞使肿瘤坏死.     

多组分植被方向反射系数的解析计算模型

基于植被介质中的辐射传输理论和几何光学原理,提出了一个计算非随机、多组分植被多波段、多角度反射光谱的综合解析模型.此模型以作者以前建立的叶冠层模型和多组分模型为基础,通过对任意空间取向植被组分对冠层“热点”效应贡献的定量计算及在多次散射系数的估算中考虑冠层所有组分的作用,全面、深入地概括了植被冠层的多种组分以及它们的几何结构和光学性质的空间变化对植被多角度反射光谱的影响。模拟与实测结果的比较得出:模型基本上能抓住多组分植被反射光谱的角度分布特征,模拟出叶冠层模型所不能得到的自然植被方向反射系数和冠层“热点”效应的非对称性分布.模型的模拟结果表明,冠层“热点”效应在冠层组分的平均倾角约20°时达最大,然后随平均倾角的增大,“热点”效应明显减弱.     

亮剑——蛋白质组学在中国

在“十一五”结束之年, 应《中国科学: 生命科学》编辑部邀请, 组织此次中国蛋白质组学专刊, 回顾我国蛋白质组学发展历程, 展示我国蛋白质组学最新成果, 同时为我国生命科学“十二五”的发展提供借鉴.

蛋白质组学是一门新兴但发展迅速的学科. 1994年, 蛋白质组概念的提出加速了蛋白质组学的凝聚和发展, 国际上主要发达国家和地区自此纷纷加大对蛋白质组学的支持力度, 蛋白质组学成为各强国科技角力新的“战场”; 至1997年, 国际蛋白质组研究已呈现蓬勃发展的势头. 我国在政府的大力支持下, 紧随其后, 较早开展了蛋白质组研究, 并迎头赶上. 过去的十余年间, 我国的蛋白质组学研究经历了最初的草创(仅少数几家单位的零星队伍), 到迅速发展、壮大, 继而走向世界, 并终于进入国际蛋白质组学研究领先行列的发展历程. ......     

具新生血管抑制及血管阻断双重作用的肿瘤血管靶向药物研究进展

以血管新生抑制剂和血管阻断剂为代表的肿瘤血管靶向药物作为一种新的抗肿瘤疗法,其研究与开发已取得显著进展,尤其是二者联用已在临床实践中获得更好疗效。因而,近年来具有新生血管抑制和血管阻断双重作用的肿瘤血管靶向药物研究备受关注。这种具双重作用的肿瘤血管靶向药物因同时保持了血管新生抑制剂和血管阻断剂的各自作用特点,在临床肿瘤治疗上更具优势,不仅能一药多靶,增强抗肿瘤疗效,同时还可降低用药剂量,减少毒副作用,提高用药耐受性,故临床应用前景广阔。综述新生血管抑制剂和血管阻断剂的作用机制及特点,介绍具代表性的兼有新生血管抑制和血管阻断双重作用的肿瘤血管靶向药物研究进展。     

肿瘤: 一种蛋白质组病

恶性肿瘤的发生是一个涉及多因素、多基因的多阶段病理过程. 以往的研究主要集中在基因组和转录组分析. 随着人类基因组计划的完成, 肿瘤研究开始进入“后基因组时代”, 肿瘤蛋白质组学应运而生. 蛋白质作为基因功能的主要执行者, 一方面在肿瘤发生发展过程中扮演重要角色, 另一方面在很大程度上决定正常细胞和肿瘤细胞之间的差异(如异型性、恶性特征等). 本文提出, 肿瘤是一种蛋白质组病, 并根据肿瘤比较蛋白质组、表达蛋白质组、功能蛋白质组和结构蛋白质组研究进展, 从肿瘤发生发展过程中蛋白质(组)表达水平及状态、蛋白质翻译后修饰、蛋白质相互作用及网络调控等三个方面进行阐述. 该观点的提出, 将为肿瘤发病机制的研究开辟新的领域, 为肿瘤的诊断(如生物标志物筛选)和筛选(如药物新靶标)提供新的思路, 具有重要的科学意义和临床应用价值.     

构建大肠杆菌药敏试验新方法的探索

基于对大肠杆菌CVCC249菌株生长动力学过程的分析表明, 导致药敏试验结果不确定性的原因主要是由于不能测计“药物浓度与菌群数量的比值”及“药物浓度及其作用时间的复合作用”对菌群生长动力学过程的影响所致. 依据菌群在一系列不同浓度的庆大霉素及其作用时间下生长受到抑制的动力学过程分析和基于差分方法, 即用简单的差分计算代替复杂的微分方程的数值解法的应用, 提出了一个药敏试验的新方法: 用菌群浊度值的净增量以消除休止细胞存在的影响后, 以菌群浊度数列递推系数值的变化, 表征药物对菌群增殖的影响, 并结合用等值线图直观显示和分析药物浓度及其作用时间复合作用的方法. 抗菌药物的抑菌率可表征为药物浓度及其作用时间的复合函数的动态变化, 表明一类抗菌药物对某一菌株抑菌率的时间或浓度依赖性, 取决于其浓度和存在时间的复合效应. 用属于不同抑菌作用机理类型的恩诺沙星、左氧氟沙星和头孢曲松钠进行对比测试, 检验了这一新方法的有效性.     

抑制血管生成治疗肿瘤的策略和展望

新生血管生成是绝大多数肿瘤得以生长和转移的必要前提。所以 ,通过抑制肿瘤血管生成来抑制肿瘤是非常有前途的一种方法 ,有望发展成为一种新型的癌症疗法。主要可以分为两大类 :一是通过抑制促血管生成信号或扩大抑制血管生成因子的作用来干扰肿瘤新生血管的形成过程 ,这领域的广泛研究已经发现了一系列促血管生成因子及其抑制剂和血管生成抑制因子 ;二是利用肿瘤血管与正常血管的差别来携带杀伤性药物直接特异性破坏已形成的肿瘤血管 ;另外 ,内皮细胞及其前体细胞制成疫苗也可起到直接杀伤作用。到目前为止 ,虽然很多抑制肿瘤血管的药物已经被用于临床试验 ,但结果往往不尽如人意 ,从长远来看 ,需要更有效的治疗方法。包括抗血管基因治疗策略 ,靶向药物导入系统的研究 ,以及抗血管生成药物和免疫疗法、化疗和放射治疗的联合应用都在探讨中。随着肿瘤模型评估系统的发展 ,抗血管治疗肿瘤的方法在不久的将来一定会广泛进入临床应用。     

以整合素αvβ3为靶点的RGD配体在抗肿瘤血管新生中的应用

整合素αvβ3是一种能特异性识别RGD序列的膜受体蛋白,其与含RGD（Arg-Gly-Asp）模体的蛋白质结合的特异性在肿瘤细胞的粘附、迁移、浸润及肿瘤血管新生中起重要作用.由于整合素αvβ3在多种肿瘤细胞表面高表达而在正常细胞中低表达或不表达,因此其成为肿瘤治疗的理想靶点.肿瘤新生血管为肿瘤的生长提供营养,因此近年来抑制肿瘤血管新生也成为肿瘤治疗的重要途径.有研究显示,几种RGD毒素蛋白不但以整合素αvβ3为靶点靶向结合到肿瘤部位从而具有直接抗肿瘤细胞增殖、黏附、迁移及浸润功能,而且它们还具有抗肿瘤血管新生的作用,因此RGD毒素蛋白可从上述两方面抑制肿瘤生长与转移.本文就整合素αvβ3为靶向的RGD配体结构特点及其在肿瘤治疗中的靶向治疗和抗血管新生应用及前景加以综述.     

荷花“重瓣化”的花器官形态发育比较观察

荷花（Nelumbo nucifera）的花型可分5种,最原始为单瓣型,然后由单瓣演化出半重瓣、重瓣、重台和千瓣型。为了揭示荷花重瓣化的分子机理,有必要从花器官的形态发育特征探究荷花花型成因及“重瓣化”的形态发育特征。实验分别选取5种荷花花型的代表品种：‘单洒锦’ （单瓣型）、‘大洒锦’ （重瓣型）、‘中山红台’ （重台型）、‘至尊千瓣’ （全重瓣型）、‘千瓣莲’ （千瓣型） 为材料,进行花芽分化过程形态的石蜡切片比较观察。结果发现：花芽分化过程中5个品种的萼片原基分化期和花瓣原基分化期相似,而雄蕊和雌蕊原基发育存在明显差异：单瓣、重瓣和重台品种均有正常的雄蕊和雌蕊原基分化;全重瓣品种发育初期有雄蕊及雌蕊原基分化,但后期全部瓣化;‘千瓣莲’品种不形成雄蕊和雌蕊原基,而是直接形成2至多个“花瓣增殖中心”,并由此不断分化出细小花瓣。研究认为重瓣型荷花品种的“重瓣化”花瓣主要来源于雄蕊的向心式瓣化,其次是雌蕊瓣化,属于雌雄蕊起源。而对于‘千瓣莲’型品种,花瓣的具体来源方式、花托是否直接参与瓣化及其在重瓣化过程中的作用有待于结合分子生物学手段开展进一步研究。     

Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?

Inhibitors of angiogenesis and radiation induce compensatory changes in the tumor vasculature both during and after cessation of treatment. In numerous preclinical studies, angiogenesis inhibitors were shown to be efficient in the treatment of many pathological conditions, including solid cancers. In most clinical trials, however, this approach turned out to have no significant effect, especially if applied as monotherapy. Recovery of tumors after therapy is a major problem in the management of cancer patients. The mechanisms underlying tumor recovery (or therapy resistance) have not yet been explicitly elucidated. This review deals with the transient switch from sprouting to intussusceptive angiogenesis, which may be an adaptive response of tumor vasculature to cancer therapy that allows the vasculature to maintain its functional properties. Potential candidates for molecular targeting of this angioadaptive mechanism are yet to be elucidated in order to improve the currently poor efficacy of contemporary antiangiogenic therapies.     

CCR6 promotes tumor angiogenesis via the AKT/NF-κB/VEGF pathway in colorectal cancer

Chemokines and chemokine receptors play an important role in tumorigenesis. Angiogenesis is a vital part of the occurrence, development and metastasis of cancer. CCR6 is an important factor during tumor progression; however, its function in tumor angiogenesis is not fully understood. In our study, we found that CCR6 was significantly overexpressed in colorectal cancer (CRC) tissues and predicted a poor prognosis in CRC patients. We then verified the function of CCR6 on tumor angiogenesis in vivo and in vitro. We observed that silencing CCR6 could decrease angiogenesis by inhibiting the proliferation and migration of human umbilical vein endothelial cells (HUVECs), whereas overexpression of CCR6 can promote angiogenesis. Additionally, we investigated the molecular mechanisms and demonstrated that activation of the AKT/NF-κB pathway maybe involved in CCR6-mediated tumor angiogenesis, which was able to promote the secretion of vascular endothelial growth factor A (VEGF-A). In conclusion, CCR6 facilitates tumor angiogenesis via the AKT/NF-κB/VEGF pathway in colorectal cancer. CCR6 inhibition may be a novel option for anti-vascular treatment in CRC.     

Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody,is associated with inhibition of tumor angiogenesis

Vascular endothelial growth factor (VEGF) and its receptors are considered the primary cause of tumor-induced angiogenesis. Specifically, VEGFR-2/kinase insert domain receptor (KDR) is part of the major signaling pathway that plays a significant role in tumor angiogenesis, which is associated with the development of various types of tumor and metastasis. In particular, KDR is involved in tumor angiogenesis as well as cancer cell growth and survival. In this study, we evaluated the therapeutic potential of TTAC-0001, a fully human antibody against VEGFR-2/KDR. To assess the efficacy of the antibody and pharmacokinetic (PK) relationship in vivo, we tested the potency of TTAC-0001 in glioblastoma and colorectal cancer xenograft models. Antitumor activity of TTAC-0001 in preclinical models correlated with tumor growth arrest, induction of tumor cell apoptosis, and inhibition of angiogenesis. We also evaluated the combination effect of TTAC-0001 with a chemotherapeutic agent in xenograft models. We were able to determine the relationship between PK and the efficacy of TTAC-0001 through in vivo single-dose PK study. Taken together, our data suggest that targeting VEGFR-2 with TTAC-0001 could be a promising approach for cancer treatment.     

Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody,is associated with inhibition of tumor angiogenesis

Vascular endothelial growth factor (VEGF) and its receptors are considered the primary cause of tumor-induced angiogenesis. Specifically, VEGFR-2/kinase insert domain receptor (KDR) is part of the major signaling pathway that plays a significant role in tumor angiogenesis, which is associated with the development of various types of tumor and metastasis. In particular, KDR is involved in tumor angiogenesis as well as cancer cell growth and survival. In this study, we evaluated the therapeutic potential of TTAC-0001, a fully human antibody against VEGFR-2/KDR. To assess the efficacy of the antibody and pharmacokinetic (PK) relationship in vivo, we tested the potency of TTAC-0001 in glioblastoma and colorectal cancer xenograft models. Antitumor activity of TTAC-0001 in preclinical models correlated with tumor growth arrest, induction of tumor cell apoptosis, and inhibition of angiogenesis. We also evaluated the combination effect of TTAC-0001 with a chemotherapeutic agent in xenograft models. We were able to determine the relationship between PK and the efficacy of TTAC-0001 through in vivo single-dose PK study. Taken together, our data suggest that targeting VEGFR-2 with TTAC-0001 could be a promising approach for cancer treatment.     

Anti-angiogenesis: making the tumor vulnerable to the immune system

Ongoing angiogenesis has been shown to possess immune suppressive activity through several mechanisms. One of these mechanisms is the suppression of adhesion receptors, such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin-adhesion molecules involved in leukocyte interactions-on the vascular endothelium. This phenomenon, when happening to the tumor endothelium, supports tumor growth due to escape from immunity. Since angiogenesis has this immune suppressive effect, it has been hypothesized that inhibition of angiogenesis may circumvent this problem. In vitro and in vivo data now show that several angiogenesis inhibitors are able to normalize endothelial adhesion molecule expression in tumor blood vessels, restore leukocyte vessel wall interactions, and enhance the inflammatory infiltrate in tumors. It is suggested that such angiogenesis inhibitors can make tumors more vulnerable for the immune system and may therefore be applied to facilitate immunotherapy approaches for the treatment of cancer.     

Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis

ABSTRACT: BACKGROUND: The epidermal growth factor receptor (EGFR) signaling pathway and angiogenesis in brain cancer act as an engine for tumor initiation, expansion and response to therapy. Since the existing literature does not have any models that investigate the impact of both angiogenesis and molecular signaling pathways on treatment, we propose a novel multi-scale, agent-based computational model that includes both angiogenesis and EGFR modules to study the response of brain cancer under tyrosine kinase inhibitors (TKIs) treatment. RESULTS: The novel angiogenesis module integrated into the agent-based tumor model is based on a set of reaction--diffusion equations that describe the spatio-temporal evolution of the distributions of micro-environmental factors such as glucose, oxygen, TGFalpha, VEGF and fibronectin. These molecular species regulate tumor growth during angiogenesis. Each tumor cell is equipped with an EGFR signaling pathway linked to a cell-cycle pathway to determine its phenotype. EGFR TKIs are delivered through the blood vessels of tumor microvasculature and the response to treatment is studied. CONCLUSIONS: Our simulations demonstrated that entire tumor growth profile is a collective behaviour of cells regulated by the EGFR signaling pathway and the cell cycle. We also found that angiogenesis has a dual effect under TKI treatment: on one hand, through neo-vasculature TKIs are delivered to decrease tumor invasion; on the other hand, the neo-vasculature can transport glucose and oxygen to tumor cells to maintain their metabolism, which results in an increase of cell survival rate in the late simulation stages.     

Effect of Melatonin on Tumor Growth and Angiogenesis in Xenograft Model of Breast Cancer

As neovascularization is essential for tumor growth and metastasis, controlling angiogenesis is a promising tactic in limiting cancer progression. Melatonin has been studied for their inhibitory properties on angiogenesis in cancer. We performed an in vivo study to evaluate the effects of melatonin treatment on angiogenesis in breast cancer. Cell viability was measured by MTT assay after melatonin treatment in triple-negative breast cancer cells (MDA-MB-231). After, cells were implanted in athymic nude mice and treated with melatonin or vehicle daily, administered intraperitoneally 1 hour before turning the room light off. Volume of the tumors was measured weekly with a digital caliper and at the end of treatments animals underwent single photon emission computed tomography (SPECT) with Technetium-99m tagged vascular endothelial growth factor (VEGF) C to detect in vivo angiogenesis. In addition, expression of pro-angiogenic/growth factors in the tumor extracts was evaluated by membrane antibody array and collected tumor tissues were analyzed with histochemical staining. Melatonin in vitro treatment (1 mM) decreased cell viability (p<0.05). The breast cancer xenografts nude mice treated with melatonin showed reduced tumor size and cell proliferation (Ki-67) compared to control animals after 21 days of treatment (p<0.05). Expression of VEGF receptor 2 decreased significantly in the treated animals compared to that of control when determined by immunohistochemistry (p<0.05) but the changes were not significant on SPECT (p>0.05) images. In addition, there was a decrease of micro-vessel density (Von Willebrand Factor) in melatonin treated mice (p<0.05). However, semiquantitative densitometry analysis of membrane array indicated increased expression of epidermal growth factor receptor and insulin-like growth factor 1 in treated tumors compared to vehicle treated tumors (p<0.05). In conclusion, melatonin treatment showed effectiveness in reducing tumor growth and cell proliferation, as well as in the inhibition of angiogenesis.     

Regulation of tumor angiogenesis by thrombospondin-1

Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.     

Cell-cycle-dependent drug-resistant quiescent cancer cells induce tumor angiogenesis after chemotherapy as visualized by real-time FUCCI imaging

We previously demonstrated that quiescent cancer cells in a tumor are resistant to conventional chemotherapy as visualized with a fluorescence ubiquitination cell cycle indicator (FUCCI). We also showed that proliferating cancer cells exist in a tumor only near nascent vessels or on the tumor surface as visualized with FUCCI and green fluorescent protein (GFP)-expressing tumor vessels. In the present study, we show the relationship between cell-cycle phase and chemotherapy-induced tumor angiogenesis using in vivo FUCCI real-time imaging of the cell cycle and nestin-driven GFP to detect nascent blood vessels. We observed that chemotherapy-treated tumors, consisting of mostly of quiescent cancer cells after treatment, had much more and deeper tumor vessels than untreated tumors. These newly-vascularized cancer cells regrew rapidly after chemotherapy. In contrast, formerly quiescent cancer cells decoyed to S/G₂ phase by a telomerase-dependent adenovirus did not induce tumor angiogenesis. The present results further demonstrate the importance of the cancer-cell position in the cell cycle in order that chemotherapy be effective and not have the opposite effect of stimulating tumor angiogenesis and progression.     

Mathematical Modeling of Interleukin-35 Promoting Tumor Growth and Angiogenesis

Interleukin-35 (IL-35), a cytokine from the Interleukin-12 cytokine family, has been considered as an anti-inflammatory cytokine which promotes tumor progression and tumor immune evasion. It has also been demonstrated that IL-35 is secreted by regulatory T cells. Recent mouse experiments have shown that IL-35 produced by cancer cells promotes tumor growth via enhancing myeloid cell accumulation and angiogenesis, and reducing the infiltration of activated CD8 T cells into tumor microenvironment. In the present paper we develop a mathematical model based on these experimental results. We include in the model an anti-IL-35 drug as treatment. The extended model (with drug) is used to design protocols of anti-IL-35 injections for treatment of cancer. We find that with a fixed total amount of drug, continuous injection has better efficacy than intermittent injections in reducing the tumor load while the treatment is ongoing. We also find that the percentage of tumor reduction under anti-IL-35 treatment improves when the production of IL-35 by cancer is increased.